SCHEMBL3974955

SCHEMBL3974955

Cc1c(-c2ccccc2)ccc(C(N)=O)c1OCCBr

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCAT2 O15382 1/20 0.43
BRD4 O60885 1/20 0.40
PSMD14 O00487 1/20 0.39
MMP2 P08253 1/20 0.39
BLM P54132 1/20 0.39
IKBKB O14920 1/20 0.38
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
HTT P42858 1/20 0.35
NR1I2 O75469 1/20 0.35
LMNA P02545 1/20 0.35
CHRM2 P08172 1/20 0.35
CYP3A4 P08684 1/20 0.35
ADRA2A P08913 1/20 0.35
MAPT P10636 1/20 0.35
OPRK1 P41145 1/20 0.35
HTR2B P41595 1/20 0.35
SLC6A3 Q01959 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
KDM4E B2RXH2 4/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3979295 0.87 BCAT2 (0.43) BCAT2BRD4PSMD14MMP2BLM
SCHEMBL3975447 0.85 BCAT2 (0.44) BCAT2BRD4IKBKBHTTKDM4E
SCHEMBL3975515 0.82 BCAT2 (0.54) BCAT2IKBKBMEN1KMT2AHTT
SCHEMBL18641956 0.80 IKBKB (0.52) BCAT2BRD4IKBKBMEN1KMT2A
SCHEMBL18816707 0.76 BCAT2 (0.45) BCAT2BRD4IKBKBMEN1KMT2A
SCHEMBL3898825 0.75 BCAT2 (0.58) BCAT2BRD4IKBKBMEN1KMT2A
SCHEMBL17829925 0.74 BCAT2 (0.56) BCAT2BRD4IKBKBMEN1KMT2A
SCHEMBL3981622 0.72 BCAT2 (0.44) BCAT2IKBKBHTTLMNAKDM4E
SCHEMBL18816701 0.71 BCAT2 (0.53) BCAT2BRD4IKBKBMEN1KMT2A
SCHEMBL3974889 0.70 MKNK1 (0.47) HTTLMNAKDM4EALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2054383-A2 NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS SmithKline Beecham Corporation (US) 2009-05-06 EP disclosed
EP-2018380-A2 CNS ACTIVE FUSED BICYCLOHETEROCYCLE SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES Abbott Laboratories (US) 2009-01-28 EP disclosed
WO-2008021849-A2 NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS SMITHKLINE BEECHAM CORPORATION (US) 2008-02-21 WO disclosed
WO-2007137030-A2 CNS ACTIVE FUSED BICYCLOHETEROCYCLE SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES ABBOTT LABORATORIES (US) 2007-11-29 WO disclosed